Hyderabad-based pharmaceutical major, Dr Reddy’s Laboratories, forayed into the transdermal patch segment with the launch of Finrid – a medicated adhesive patch used in the management of severe to moderate pain – in the Indian market.
In-licensed from Sparsha Pharma, Finrid, which delivers dosages of 25 mcg (microgram) per hour and 50 mcg per hour depending on the patch used, will be sold through an independent distribution structure and will be available across hospitals and palliative care centres in India, the company said in a press release.
The scrip of Dr Reddy’s is currently trading at Rs 815 on the BSE, up 0.11 per cent as against the previous close of Rs 814.10.
